Form 4: United Therapeutics Director Exercises Stock Options and Sells Shares

A director at United Therapeutics Corp. exercised stock options and subsequently sold a portion of the acquired shares in a cashless transaction.

Summary

• Richard Giltner, a Director of United Therapeutics Corp. (UTHR), reported changes in his beneficial ownership of the company's common stock.
• On June 24, 2025, Mr. Giltner acquired 5,000 shares of common stock through the exercise of stock options at an exercise price of $175.43 per share.
• Concurrently, on June 24, 2025, Mr. Giltner disposed of 3,036 shares of common stock at a price of $289.5962 per share.
• This disposition was part of a cashless sell-to-cover transaction, where shares were sold to cover the exercise price of the options.
• Following these transactions, Mr. Giltner's direct beneficial ownership of United Therapeutics common stock stands at 19,384 shares.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (option exercise and sell-to-cover) which is neutral in sentiment. It does not indicate significant positive or negative news about the company's operations or financial health.

Positives

• The exercise of stock options indicates that the options were in-the-money, allowing the director to realize value from their compensation.
• The director retained 1,964 shares (5,000 acquired 3,036 sold) from the option exercise, increasing their overall direct beneficial ownership.

Negatives

• The sale of 3,036 shares, even for tax and exercise cost coverage, represents a reduction in the director's direct equity stake in the company.

Future Outlook

This Form 4 filing reports past transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This document is an individual insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects a routine compensation-related transaction for a company director.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and is unlikely to have a significant direct impact on the company's share price or shareholder value. It provides transparency into director stock ownership changes.

Key Dates

Keywords

United Therapeutics, UTHR, SEC Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Beneficial Ownership, Director Transaction, Cashless Sell-to-Cover